Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Livio Azzoni

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Frontiers in Molecular Biosciences|May 14, 2026
Circulating plasma protein biomarkers associated with risk of negative clinical outcomes in virally suppressed people with HIV receiving medications for opioid use disorderLivio Azzoni, Liao Zhang, Kaiyi Zhu, et al.
AIDS Research and Human Retroviruses|September 16, 2008
HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjectsEmmanouil Papasavvas, Elizabeth C Moore, Junwei Sun, et al.
Journal of Leukocyte Biology|November 27, 2015
Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activationSean C Patro, Livio Azzoni, Jocelin Joseph, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 24, 2002
Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individualsJihed Chehimi, Donald E Campbell, Livio Azzoni, et al.
Immunology|February 17, 2015
Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patientsEmmanouil Papasavvas, Andrea Foulkes, Xiangfan Yin, et al.
Plos One|March 4, 2014
Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infectionNoor Dawany, Louise C Showe, Andrew V Kossenkov, et al.
AIDS (London, England)|July 26, 2018
Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIVEmmanouil Papasavvas, Steven M Lada, Jocelin Joseph, et al.
AIDS (London, England)|June 6, 2008
Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapyEmmanouil Papasavvas, Livio Azzoni, Maxwell Pistilli, et al.
AIDS (London, England)|January 27, 2007
Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cellsLivio Azzoni, Jihed Chehimi, Lan Zhou, et al.
AIDS (London, England)|May 28, 2021
Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruptionEmmanouil Papasavvas, Livio Azzoni, Brian N Ross, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Frontiers in Molecular Biosciences|May 14, 2026
Circulating plasma protein biomarkers associated with risk of negative clinical outcomes in virally suppressed people with HIV receiving medications for opioid use disorderLivio Azzoni, Liao Zhang, Kaiyi Zhu, et al.
AIDS Research and Human Retroviruses|September 16, 2008
HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjectsEmmanouil Papasavvas, Elizabeth C Moore, Junwei Sun, et al.
Journal of Leukocyte Biology|November 27, 2015
Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activationSean C Patro, Livio Azzoni, Jocelin Joseph, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 24, 2002
Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individualsJihed Chehimi, Donald E Campbell, Livio Azzoni, et al.
Immunology|February 17, 2015
Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patientsEmmanouil Papasavvas, Andrea Foulkes, Xiangfan Yin, et al.
Plos One|March 4, 2014
Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infectionNoor Dawany, Louise C Showe, Andrew V Kossenkov, et al.
AIDS (London, England)|July 26, 2018
Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIVEmmanouil Papasavvas, Steven M Lada, Jocelin Joseph, et al.
AIDS (London, England)|June 6, 2008
Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapyEmmanouil Papasavvas, Livio Azzoni, Maxwell Pistilli, et al.
AIDS (London, England)|January 27, 2007
Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cellsLivio Azzoni, Jihed Chehimi, Lan Zhou, et al.
AIDS (London, England)|May 28, 2021
Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruptionEmmanouil Papasavvas, Livio Azzoni, Brian N Ross, et al.
Pageof 5